Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 297

1.

Chronic kidney failure mineral bone disorder leads to a permanent loss of hematopoietic stem cells through dysfunction of the stem cell niche.

Aleksinskaya MA, Monge M, Siebelt M, Slot EM, Koekkoek KM, de Bruin RG, Massy ZA, Weinans H, Rabelink TJ, Fibbe WE, Jan van Zonneveld A, van Pel M.

Sci Rep. 2018 Oct 18;8(1):15385. doi: 10.1038/s41598-018-33979-7.

2.

Second-line treatment for acute graft-versus-host disease with mesenchymal stromal cells: A decision model.

Thielen FW, Blommestein HM, Oosten LEM, Calkoen FG, Lankester AC, Zwaginga JJ, Le Blanc K, Redondo A, Sánchez-Guijo F, Algeri M, Locatelli F, Fibbe WE, Uyl-de Groot CA.

Eur J Haematol. 2018 Aug 6. doi: 10.1111/ejh.13158. [Epub ahead of print]

PMID:
30084111
3.

No Clinical Benefit of Intramuscular Delivery of Bone Marrow-derived Mononuclear Cells in Nonreconstructable Peripheral Arterial Disease: Results of a Phase-III Randomized-controlled Trial.

Lindeman JHN, Zwaginga JJ, Kallenberg-Lantrua G, van Wissen RC, Schepers A, van Bockel HJ, Fibbe WE, Hamming JF.

Ann Surg. 2018 Nov;268(5):756-761. doi: 10.1097/SLA.0000000000002896.

PMID:
30004916
4.

Mesenchymal stromal cells induce a permissive state in the bone marrow that enhances G-CSF-induced hematopoietic stem cell mobilization in mice.

de Kruijf EFM, Zuijderduijn R, Stip MC, Fibbe WE, van Pel M.

Exp Hematol. 2018 Aug;64:59-70.e2. doi: 10.1016/j.exphem.2018.05.002.

PMID:
29775645
5.

Safety and efficacy of percutaneous intramyocardial bone marrow cell injection for chronic myocardial ischemia: Long-term results.

Rodrigo SF, Mann I, van Ramshorst J, Beeres SL, Zwaginga JJ, Fibbe WE, Bax JJ, Schalij MJ, Atsma DE.

J Interv Cardiol. 2017 Oct;30(5):440-447. doi: 10.1111/joic.12408. Epub 2017 Jul 28.

PMID:
28752630
6.

Lupus nephritis: Mesenchymal stromal cells in lupus nephritis.

Fibbe WE, Rabelink TJ.

Nat Rev Nephrol. 2017 Jul 18;13(8):452-453. doi: 10.1038/nrneph.2017.100. No abstract available.

PMID:
28719600
7.

Clinical-Grade Isolated Human Kidney Perivascular Stromal Cells as an Organotypic Cell Source for Kidney Regenerative Medicine.

Leuning DG, Reinders ME, Li J, Peired AJ, Lievers E, de Boer HC, Fibbe WE, Romagnani P, van Kooten C, Little MH, Engelse MA, Rabelink TJ.

Stem Cells Transl Med. 2017 Feb;6(2):405-418. doi: 10.5966/sctm.2016-0053. Epub 2016 Sep 20.

8.

Discrepant Results of Experimental Human Mesenchymal Stromal Cell Therapy after Myocardial Infarction: Are Animal Models Robust Enough?

den Haan MC, van Zuylen VL, Pluijmert NJ, Schutte CI, Fibbe WE, Schalij MJ, Roelofs H, Atsma DE.

PLoS One. 2016 Apr 6;11(4):e0152938. doi: 10.1371/journal.pone.0152938. eCollection 2016.

9.

A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema.

Stolk J, Broekman W, Mauad T, Zwaginga JJ, Roelofs H, Fibbe WE, Oostendorp J, Bajema I, Versteegh MI, Taube C, Hiemstra PS.

QJM. 2016 May;109(5):331-6. doi: 10.1093/qjmed/hcw001. Epub 2016 Jan 27.

10.

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials.

Galipeau J, Krampera M, Barrett J, Dazzi F, Deans RJ, DeBruijn J, Dominici M, Fibbe WE, Gee AP, Gimble JM, Hematti P, Koh MB, LeBlanc K, Martin I, McNiece IK, Mendicino M, Oh S, Ortiz L, Phinney DG, Planat V, Shi Y, Stroncek DF, Viswanathan S, Weiss DJ, Sensebe L.

Cytotherapy. 2016 Feb;18(2):151-9. doi: 10.1016/j.jcyt.2015.11.008. Epub 2015 Dec 23.

11.

The human and murine hematopoietic stem cell niches: are they comparable?

van Pel M, Fibbe WE, Schepers K.

Ann N Y Acad Sci. 2016 Apr;1370(1):55-64. doi: 10.1111/nyas.12994. Epub 2015 Dec 29. Review.

PMID:
26713726
12.

Unraveling mechanisms of mesenchymal stromal cell-mediated immunomodulation through patient monitoring and product characterization.

Schepers K, Fibbe WE.

Ann N Y Acad Sci. 2016 Apr;1370(1):15-23. doi: 10.1111/nyas.12984. Epub 2015 Dec 29. Review.

PMID:
26713608
13.

Visualizing Human Hematopoietic Stem Cell Trafficking In Vivo Using a Zebrafish Xenograft Model.

Staal FJ, Spaink HP, Fibbe WE.

Stem Cells Dev. 2016 Feb 15;25(4):360-5. doi: 10.1089/scd.2015.0195. Epub 2016 Jan 19.

PMID:
26650921
14.

Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.

Reinders ME, Dreyer GJ, Bank JR, Roelofs H, Heidt S, Roelen DL, Zandvliet ML, Huurman VA, Fibbe WE, van Kooten C, Claas FH, Rabelink TJ, de Fijter JW.

J Transl Med. 2015 Nov 4;13:344. doi: 10.1186/s12967-015-0700-0.

15.

Development of a diverse human T-cell repertoire despite stringent restriction of hematopoietic clonality in the thymus.

Brugman MH, Wiekmeijer AS, van Eggermond M, Wolvers-Tettero I, Langerak AW, de Haas EF, Bystrykh LV, van Rood JJ, de Haan G, Fibbe WE, Staal FJ.

Proc Natl Acad Sci U S A. 2015 Nov 3;112(44):E6020-7. doi: 10.1073/pnas.1519118112. Epub 2015 Oct 19.

16.

Reduction of healthcare utilization after bone marrow cell therapy for refractory angina pectoris.

Rodrigo SF, Mann I, van Ramshorst J, Beeres SL, Zwaginga JJ, Fibbe WE, Bax JJ, Schalij MJ, Atsma DE.

Int J Cardiol. 2016 Jan 1;202:571-2. doi: 10.1016/j.ijcard.2015.09.103. Epub 2015 Sep 28. No abstract available.

PMID:
26447664
17.

Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells.

Wiekmeijer AS, Pike-Overzet K, IJspeert H, Brugman MH, Wolvers-Tettero IL, Lankester AC, Bredius RG, van Dongen JJ, Fibbe WE, Langerak AW, van der Burg M, Staal FJ.

J Allergy Clin Immunol. 2016 Feb;137(2):517-526.e3. doi: 10.1016/j.jaci.2015.08.022. Epub 2015 Oct 4.

PMID:
26441229
18.

Repeated Intramyocardial Bone Marrow Cell Injection in Previously Responding Patients With Refractory Angina Again Improves Myocardial Perfusion, Anginal Complaints, and Quality of Life.

Mann I, Rodrigo SF, van Ramshorst J, Beeres SL, Dibbets-Schneider P, de Roos A, Wolterbeek R, Zwaginga JJ, Fibbe WE, Bax JJ, Schalij MJ, Atsma DE.

Circ Cardiovasc Interv. 2015 Aug;8(8). pii: e002740. doi: 10.1161/CIRCINTERVENTIONS.115.002740.

PMID:
26259770
19.

Myocardial infarction models in NOD/Scid mice for cell therapy research: permanent ischemia vs ischemia-reperfusion.

van Zuylen VL, den Haan MC, Roelofs H, Fibbe WE, Schalij MJ, Atsma DE.

Springerplus. 2015 Jul 10;4:336. doi: 10.1186/s40064-015-1128-y. eCollection 2015.

20.

Preconditioning allows engraftment of mouse and human embryonic lung cells, enabling lung repair in mice.

Rosen C, Shezen E, Aronovich A, Klionsky YZ, Yaakov Y, Assayag M, Biton IE, Tal O, Shakhar G, Ben-Hur H, Shneider D, Vaknin Z, Sadan O, Evron S, Freud E, Shoseyov D, Wilschanski M, Berkman N, Fibbe WE, Hagin D, Hillel-Karniel C, Krentsis IM, Bachar-Lustig E, Reisner Y.

Nat Med. 2015 Aug;21(8):869-79. doi: 10.1038/nm.3889. Epub 2015 Jul 13.

PMID:
26168294

Supplemental Content

Loading ...
Support Center